Allergan, Actavis Nearing Deal to Combine, WSJ Reports
2014-11-16 18:34:50.995 GMT
By Sylvia Wier
Nov. 16 (Bloomberg) -- Allergan Inc. and Actavis Plc are
close to a combination that would thwart hostile efforts by
Valeant Pharmaceuticals International Inc., the Wall Street
Journal reported, citing unidentified people familiar with the
matter.
The deal would be cash and stock and could be announced as
early as tomorrow, the Journal said, citing the people.
Separately, CNBC reporter David Faber tweeted today that
the deal could worth more than $210 a share.
Link to Company News:{VRX CN <Equity> CN <GO>}
Link to Company News:{ACT US <Equity> CN <GO>}
Link to Company News:{AGN US <Equity> CN <GO>}
Link to Company News:{2638211Z US <Equity> CN <GO>}
For Related News and Information:
Top Stories:{TOP<GO>}
To contact the editor responsible for this story:
Sylvia Wier at +1-212-617-8958 or
swier@bloomberg.net
2014-11-16 18:34:50.995 GMT
By Sylvia Wier
Nov. 16 (Bloomberg) -- Allergan Inc. and Actavis Plc are
close to a combination that would thwart hostile efforts by
Valeant Pharmaceuticals International Inc., the Wall Street
Journal reported, citing unidentified people familiar with the
matter.
The deal would be cash and stock and could be announced as
early as tomorrow, the Journal said, citing the people.
Separately, CNBC reporter David Faber tweeted today that
the deal could worth more than $210 a share.
Link to Company News:{VRX CN <Equity> CN <GO>}
Link to Company News:{ACT US <Equity> CN <GO>}
Link to Company News:{AGN US <Equity> CN <GO>}
Link to Company News:{2638211Z US <Equity> CN <GO>}
For Related News and Information:
Top Stories:{TOP<GO>}
To contact the editor responsible for this story:
Sylvia Wier at +1-212-617-8958 or
swier@bloomberg.net